Related Experiment Video
Updated: Mar 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Giulia Bruzzone, Giorgia Corbelli, Paola Belci
1Department of Internal Medicine University of Genoa Viale Benedetto XV 6 16132 Genoa, Italy.
Insights
Residual risk in Atherosclerotic Cardiovascular Disease (ASCVD) persists despite statin therapy. Factors like dyslipidemia, genetics, and lifestyle contribute to this risk, necessitating further research for improved cardiovascular disease prevention.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Atherosclerotic Cardiovascular Disease (ASCVD) is a leading cause of mortality in Western countries.
- Statin therapy reduces ASCVD mortality but a significant residual risk remains even at low-density lipoprotein cholesterol (LDL-C) goals.
Purpose of the Study:
- To review literature on residual dyslipidemia, genetic factors, lifestyle, and mood disorders contributing to residual cardiovascular risk.
- To discuss the current understanding and contradictory aspects of these factors in ASCVD.
Main Methods:
- Literature review of studies published in PubMed.
- Focus on high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), lipoprotein(a) [Lp(a)], genetic factors, and lifestyle implementation.
Main Results:
- The classical HDL hypothesis is outdated; HDL function is now considered more critical.
- The relationship between TGs and cardiovascular risk is not definitive.
- APOE genotype and Lp(a) levels are identified genetic risk factors.
Conclusions:
- HDL function requires further validation.
- Lifestyle and psychological factors play a crucial role in managing global cardiovascular risk.
- Addressing residual risk factors beyond LDL-C is essential for ASCVD prevention.
Background:
Atherosclerotic Cardiovascular Disease (ASCVD) is the first cause of death in Western Countries. Several risk factors contribute to generate atherosclerosis and the preventive therapeutic approaches, in particular statin therapy, reduce the mortality. However, the residual risk in statin treated patients remains significant, despite reaching the low density lipoproteins cholesterol (LDL-C) goals.
Methods:
we reviewed the literature published in PUB-MED to discuss the role of residual dyslipidemia in particular high density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein(a) [Lp(a)], genetic factors, suboptimal implementation of lifestyle therapy, mood disorders associated to low compliance to application of evidence-based therapies or related to ASCVD.
Results:
we summarized the current knowledge on the topic, evidencing its contradictory aspects.
Conclusion:
HDL-C is an important biomarker for predicting cardiovascular risk, but the classical HDL hypothesis is no longer correct and it is now being replaced by the HDL function hypothesis, thought more studies are needed to validate it. The connection between cardiovascular risk and levels of TGs is not so definite. APOE genotype and Lp(a) levels are two genetics factors associated to CV risk. Healthy lifestyle with particular dietetic factors, connected to psychological aspects, are very important for the optimal control of the global risk.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Lipids: Dietary Sources and Requirements

